The AGE-RAGE-DIAPH1 Axis in Type 2 Diabetes and Metabolic Dysfunction: From Carbonyl Stress to Diabetic Myocardial and Neuronal Injury.
Level 5 - mechanism / opinion, no new human data
Narrative mechanistic review without primary human trial data or systematic synthesis
PubMed 42353026 · doi:10.3390/ijms27125305
What was done
This narrative review synthesized literature on the AGE-RAGE-DIAPH1 signaling axis as a mechanistic contributor to diabetic myocardial, vascular, and autonomic neuronal injury in type 2 diabetes mellitus and obesity. The authors evaluated evidence across experimental models regarding advanced glycation end-product accumulation, DIAPH1 intracellular signaling, associated tissue remodeling, proposed biomarkers (such as circulating AGEs and soluble RAGE isoforms), and potential pharmacological targets.
What was found
The abstract reports no numerical data or quantitative effect sizes. Across experimental models, activation of the signaling axis promotes oxidative stress, inflammation, endothelial dysfunction, cardiomyocyte calcium handling abnormalities, and myocardial fibrosis. In the autonomic nervous system, RAGE activation is linked to mitochondrial dysfunction and abnormal excitability; however, direct evidence specifically linking DIAPH1 to autonomic neuronal damage or validating its role as a clinical biomarker or drug target in human neurocardiac complications is lacking.
Why it matters
It outlines how the AGE-RAGE signaling pathway contributes to diabetic cardiovascular and neural complications, while clearly delineating the boundary between established AGE-RAGE biology and the unproven translational hypothesis regarding DIAPH1 targeting.
Limits
As a narrative review, it reports no new human data, sample sizes, or systematic meta-analytic synthesis. The proposed mechanisms rely largely on preclinical models, and direct clinical evidence for DIAPH1 engagement in human pathology is absent.
Cited by
- supports Glycated proteins are highly inflammatory in the human body.